Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.67), $0.03 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $16.51 million versus the consensus estimate of $13.93 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.